Role of Anthracyclines in the Treatment of Adult Acute Lymphoblastic Leukemia

Acta Haematologica

Volumn 95, Issue 3-4, 1996, Pages 188-192

  Bassan, Renato ^a   Lerede, Teresa ^a   Rambaldi, Alessandro ^a   Barbu, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Adult ALL; Anthracyclines; Chemotherapy

Indexed keywords

ANTHRACYCLINE; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; DAUNORUBICIN; DOXORUBICIN; IDARUBICIN; METHOTREXATE; MITOXANTRONE; ZORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 22; CHROMOSOME TRANSLOCATION 9; CONFERENCE PAPER; HUMAN; LEUKEMIA REMISSION; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS; DAUNORUBICIN; DOXORUBICIN; HUMANS; IDARUBICIN; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; REMISSION INDUCTION;

EID: 0029919135     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203876     Document Type: Article

References (22)

1. Young RC, Ozols RF, Myers CE: The anthra-cycline antineoplastic drugs. N Engl J Med 1981;305:139-153.
2. D'Incalci M, Capranico G, Giaccone G, Zuni-no F, Garattini S: DNA topoisomerase inhibitors. Cancer Chemother Biol Response Modif 1993;14:61-85.
3. Kuflcl MJ, Reid JM, Ames MM: Anthracy-clines and their C-13 alcohol metabolites: Growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol 1992,30:51-57.
4. Ames MM, Spreafico F: Selected pharmacologic characteristic of idarubicin and idarubici-nol. Leukemia 1992;6(suppl 1):70—75.
5. Zanette L, Zucchetti M, Freshi A, Erranti D, Tirelli U, D'Incalci M: Pharmacokinetics of 4-demcthoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 1990:25:445— 448.
6. Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:3267-3273.
7. Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C: Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow' progenitors in relation to their proliferative state. Leukemia 1994;8:382-387.
8. Curtis JE, Minden MD, Minkin S, McCulloch EA: Sensitivities of AML blast stem cells to idarubicin and daunorubicin: A comparison with normal hematopoietic progenitors. Leukemia 1995;9:396-404.
9. Berman E, Heller G, Santorsa JA, McKenzie S, Gce T, Kempin S, Gulati S, Andrceff M, Kolitz J, Gabrilovc J, Reich L, Mayer K, Keefe D, Trainor K, Schluger A, Penenberg D, Raymond V, O'Reilly R, Jhanwar S, Young C, Clarkson B: Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666— 1674.
10. Wiernik PH, Banks PLC, Case DC, Arlin ZA, Periman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB: Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79: 313-319.
11. Vogler WR, Vclez-Garcia E, Weiner RS, Flaum MA, Bartolucci AA, Omura GA, Gerber MC, Banks PLC: A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 1992; 10:1103-1111.
12. Gottlieb AJ, Weinberg V, Ellison RR, Henderson HE, Terebelo H, Rafla S, Cuttncr J, Silver RT, Carey RW, Levy RN, Hutchinson JL, Raich P, Cooper MR, Wiernik P, Anderson JR. Holland JF: Efficacy of daunorubicin in the therapy of adult lymphocytic leukemia: A prospective randomized trial by Cancer and Leukemia Group B. Blood 1984:64:267-274.
13. Ellison RR. Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES, Woliver T, Royston I, Davcy FR. Glicksman AS, Bloomfield CD. Holland JF: The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: A prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol 1991; 9:2002-2015.
14. Rohatiner AZS, Lister TA: The challenge of acute lymphoblastic leukaemia in adults. Br J Haematol 1993;85:641-645.
15. Preti A, Kantarjian HM: Management of adult acute lymphocytic leukemia: Present issues and key challenges. J Clin Oncol 1994; 12: 1312-1322.
16. Hoclzer D: Treatment of acute lymphoblastic leukemia. Semin Hematol 1994;31:1-15.
17. Proctor SJ: Acute lymphoblastic leukaemia in adults: The case for a strategic shift in study approach. Br J Haematol 1994;88:229-233.
18. Todeschini G, Meneghini V, Pizzolo G, Cas-sibba V, Ambrosetti A, Veneri D, Nadali G, Zanotti R, Tecchio C, Perona G: Relationship between daunorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994;8: 376-381.
19. Bassan R, Battista R, Rohatiner AZS, Love S, Carter M, Buelli M, Viero P, D’Emilio A, Mac-Callum P, Amcss J, Dini E, Barbui T, Lister TA: Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period. Leukemia 1992;6(suppl 2): 186—190.
20. Bassan R, Battista R, Viero P, Pogliani E, Rossi G, Lambertenghi-Deliliers G, Rambaldi S, D’Emilio A, Buelli M, Borleri G, Corneo G, Dini E, Barbui T: Intensive therapy for adult acute lymphoblastic leukemia: Preliminary results of the idarubicin/vincristine//.-asparagin-asc/prednisolonc regimen. Semin Oncol 1993; 20(suppl 8):39-46.
21. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T: The use of anthracyclines in adult acute lymphoblastic leukemia. Haemato-logica 1995;80:280-291.
22. Larson RA, Linker CA, Dodge RK. George SL, Davey FR, Frankel SR, Powell BL, Schiffer CA: Granulocytc-colony stimulating factor (filgrastim: G-CSF) reduces the time to neutrophil recovery in adults with acute lymphoblastic leukemia receiving intensive remission induction chemotherapy: Cancer and Leukemia Group B study 9111 (abstract). Proc Am Soc Clin Oncol 1994; 13:305.